Novel Delivery of Pancreatic Islet Cells to Treat Insulin-Dependent Diabetes Mellitus
- 1 June 1995
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 28 (6) , 471-482
- https://doi.org/10.2165/00003088-199528060-00005
Abstract
Immune protective devices containing pancreatic islets are designed to treat insulin-dependent diabetes mellitus by providing glycaemic control without immunosuppression. The immune protection is achieved by separating allogeneic or xenogeneic islets from the host by semipermeable membranes that allow only small molecules such as glucose, insulin and nutrients to pass through. Lymphocytes and immunoglobulins are excluded by the membrane and unable to cause rejection of the islets. Three types of immune protective devices, i.e. microcapsules, diffusion chambers and perfusion devices (vascularised artificial pancreas), have been studied. Microcapsules injected into the abdominal cavity in a large quantity achieved glycaemic control, but required a small amount of immunosuppression to prevent fibrosis around the capsules. A clinical attempt to use microcapsulated human islets in a diabetic patient who has maintained functional kidney allografts has been reported. Intra-abdominal placement of diffusion chambers containing allogeneic islets achieved excellent glycaemic control without immunosuppression in diabetic dogs. However, their use was limited by the eventual breakage of tubular chambers. We have extensively used the vascularised artificial pancreas for treatment of experimental diabetes mellitus. Excellent biocompatibility of the device was evidenced by the extraordinary longevity of the patency of the device in healthy dogs. Long term control of severe diabetes mellitus was achieved in totally pancreatectomised dogs without immunosuppression by devices seeded with allogeneic (canine) and xenogeneic (porcine) islets. The vascularised artificial pancreas could be an excellent alternative to Diabetes Control and Complication Trial (DCCT)-type intensive insulin therapy or pancreatic transplantation by providing tight glycaemic control with minimal exogenous insulin therapy without immunosuppression.This publication has 19 references indexed in Scilit:
- The DCCT and Medical Care for Diabetes in the U. S.Diabetes Care, 1994
- Insulin independence in a type 1 diabetic patient after encapsulated islet transplantationThe Lancet, 1994
- TREATMENT OF SEVERE DIABETES MELLITUS FOR MORE THAN ONE YEAR USING A VASCULARIZED HYBRID ARTIFICIAL PANCREASTransplantation, 1993
- Quantitation of comparative thrombogenicity of dog, pig, and human platelets in a hemodialyzer.1992
- Xenotransplantation of canine, bovine, and porcine islets in diabetic rats without immunosuppression.Proceedings of the National Academy of Sciences, 1991
- Complications Associated with Immunosuppressive Therapy and Their ManagementPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1991
- Biohybrid Artificial Pancreas: Long-Term Implantation Studies in Diabetic, Pancreatectomized DogsScience, 1991
- SUCCESSFUL TREATMENT OF DIABETES WITH THE BIOHYBRID ARTIFICIAL PANCREAS IN DOGSTransplantation, 1991
- Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membraneBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1984
- Microencapsulated Islets as Bioartificial Endocrine PancreasScience, 1980